Can Hepatitis B Be Cured?
Hepatitis B cannot be completely cured with current treatments, but a "functional cure" (defined as sustained loss of hepatitis B surface antigen [HBsAg] with undetectable HBV DNA) is achievable in a small percentage of patients. 1
Why Complete Cure Is Not Possible
Current antiviral therapies cannot eradicate hepatitis B virus because:
- Covalently closed circular DNA (cccDNA) persists in the nuclei of infected liver cells 2, 3
- Integrated HBV DNA remains in the host genome 4, 5
- These viral reservoirs continue to produce viral antigens even when viral replication is suppressed
This fundamental biological barrier means that HBV infection cannot be completely eliminated from the body with existing medications.
What Current Treatment Can Achieve
Functional Cure (The Optimal Endpoint)
Functional cure means sustained HBsAg loss with undetectable HBV DNA after treatment, which allows safe discontinuation of therapy 1, 6. However, this outcome is rare with current treatments:
- Nucleos(t)ide analogues (NAs) after 10 years: Only 3-5% achieve HBsAg loss 3, 7
- Pegylated interferon after 3-5 years: 8-14% achieve HBsAg loss 7
- Even after functional cure, HCC can still develop (annual rate ~0.55%), though risk is substantially lower 1
Viral Suppression (The Realistic Goal)
Long-term suppression of HBV replication to undetectable levels is the main achievable endpoint that prevents disease progression 1. This requires:
- Indefinite treatment with potent nucleos(t)ide analogues (entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) 6
- Continuous viral suppression prevents cirrhosis, liver decompensation, and reduces (but does not eliminate) HCC risk 3, 1
Clinical Benefits Despite Lack of Complete Cure
Effective antiviral therapy dramatically improves outcomes even without achieving cure 3:
- Reverses liver fibrosis and cirrhosis
- Prevents progression to hepatic decompensation
- Significantly reduces HCC risk (though does not eliminate it)
- Prevents liver-related mortality
- Reduces transmission to others
Important Caveats
Stopping nucleos(t)ide analogue therapy almost always leads to viral relapse, even after years of undetectable HBV DNA 3. Treatment cessation should only be considered:
- After achieving HBsAg loss (functional cure)
- In carefully selected non-cirrhotic patients under rigorous monitoring 7
- Never in patients with cirrhosis, who require indefinite treatment 3, 1
HCC surveillance must continue even with successful viral suppression because the risk persists, particularly in those with:
Future Prospects
Novel therapies in development aim to achieve higher rates of functional cure through 4, 5:
- Direct-acting antivirals targeting different stages of the HBV life cycle
- Immunomodulatory approaches to restore HBV-specific immune responses
- Combination strategies addressing viral reservoirs, antigen burden, and immune dysfunction
Until these new therapies become available, the realistic treatment goal remains lifelong viral suppression rather than cure 3, 9.